4.7 Article

Ginsenoside Rb1 alleviates diabetic kidney podocyte injury by inhibiting aldose reductase activity

Journal

ACTA PHARMACOLOGICA SINICA
Volume 43, Issue 2, Pages 342-353

Publisher

NATURE PUBL GROUP
DOI: 10.1038/s41401-021-00788-0

Keywords

diabetickidney disease; ginsenoside Rb1; podocyte apoptosis; oxidative stress; aldose reductase; Cyto c; NOX4; eparestat

Funding

  1. National Key Research and Development Plan of China [2018YFC1704203]
  2. National Natural Science Foundation of China [81670671, 81870491, 82070741]
  3. Science & Technology Project of Beijing, China [D171100002817002]
  4. Fostering Fund of Chinese PLA General Hospital for National Distinguished Young Scholar Science Fund [2019-JQPY-002]

Ask authors/readers for more resources

Panax notoginseng, a traditional Chinese medicine, has beneficial effects on diabetic kidney disease (DKD) by alleviating podocyte injury through inhibiting apoptosis and mitochondrial damage. Rb1, the main active ingredient of Panax notoginseng, combines with aldose reductase to effectively mitigate the progression of diabetic kidney disease.
Panax notoginseng, a traditional Chinese medicine, exerts beneficial effect on diabetic kidney disease (DKD), but its mechanism is not well clarified. In this study we investigated the effects of ginsenoside Rb1 (Rb1), the main active ingredients of Panax notoginseng, in alleviating podocyte injury in diabetic nephropathy and the underlying mechanisms. In cultured mouse podocyte cells, Rb1 (10 mu M) significantly inhibited high glucose-induced cell apoptosis and mitochondrial injury. Furthermore, Rb1 treatment reversed high glucose-induced increases in Cyto c, Caspase 9 and mitochondrial regulatory protein NOX4, but did not affect the upregulated expression of aldose reductase (AR). Molecular docking analysis revealed that Rb1 could combine with AR and inhibited its activity. We compared the effects of Rb1 with eparestat, a known aldose reductase inhibitor, in high glucose-treated podocytes, and found that both alleviated high glucose-induced cell apoptosis and mitochondrial damage, and Rb1 was more effective in inhibiting apoptosis. In AR-overexpressing podocytes, Rb1 (10 mu M) inhibited AR-mediated ROS overproduction and protected against high glucose-induced mitochondrial injury. In streptozotocin-induced DKD mice, administration of Rb1 (40 mg center dot kg(-1)center dot d(-1), ig, for 7 weeks) significantly mitigated diabetic-induced glomerular injuries, such as glomerular hypertrophy and mesangial matrix expansion, and reduced the expression of apoptotic proteins. Collectively, Rb1 combines with AR to alleviate high glucose-induced podocyte apoptosis and mitochondrial damage, and effectively mitigates the progression of diabetic kidney disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available